Maxim Group analyst Jason Kolbert came out with an update on Brainstorm Cell Therapeutics (NASDAQ:BCLI), as the company announced that it received a Notice of Allowance from …
Maxim’s healthcare analyst Jason Kolbert weighed in with his thoughts on Galena Biopharma (NASDAQ:GALE), after the company announced enrollment of the 700th patient in the …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, as …
In a research report published Monday, Maxim analyst Jason Kolbert maintained a Buy rating on Pluristem Therapeutics (NASDAQ:PSTI) with an $8.00 price target, …
Maxim’s healthcare analyst Jason Kolbert is weighing in with an update on Intellipharmaceutics International (NASDAQ:IPCI), as the company announced the it has signed a license agreement …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Athersys (NASDAQ:ATHX) and raised his price target …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Tekmira Pharma (NASDAQ:TKMR) with a $27 price …
Maxim’s healthcare analyst Jason Kolbert weighed in today with his thoughts on IsoRay Inc (NYSE:ISR), as the company announced that researchers at the University of Pittsburgh School …
In a research report released Friday, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a $7 price target, …
In a research report released this morning, Maxim Group analyst Jason Kolbert maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price …
